+33,480.5%
MCHP vs GSK
+1,067.3%
+32,413.2%
-63.8%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.9% | -0.1% | -4.8% | -4.9% |
| 7D | -4.7% | -1.3% | -3.3% | -4.2% |
| 30D | -20.6% | +2.7% | -23.3% | -21.5% |
| 3M | -25.5% | +2.7% | -28.2% | -26.7% |
| 6M | -36.8% | +3.3% | -40.2% | -38.4% |
| YTD | -6.4% | +6.5% | -12.9% | -10.4% |
| 1Y | +12.5% | +10.7% | +1.9% | +6.2% |
| 3Y | -23.0% | +64.4% | -87.4% | -39.3% |
| 5Y | -22.4% | +46.7% | -69.1% | -37.1% |
| 10Y | +115.8% | +109.4% | +6.4% | +53.0% |
| All | +33,480.5% | +1,067.3% | +32,413.2% | +16,273.8% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling